| Authors: |
Potashman MH; Biohaven Pharmaceuticals, Inc., New Haven, CT, USA. Electronic address: michele.potashman@biohavenpharma.com., Rudell K; COA Science, Parexel International, London, UK., Abetz-Webb L; Patient-Centered Outcomes Assessments, Macclesfield, UK., Suminski N; COA Science, Parexel International, London, UK., Gold A; COA Science, Parexel International, London, UK., Doma R; COA Science, Parexel International, London, UK., Jarodia K; COA Science, Parexel International, London, UK., Buckley C; COA Science, Parexel International, London, UK., Ridley M; COA Science, Parexel International, London, UK., Lerner J; Biohaven Pharmaceuticals, Inc., New Haven, CT, USA., Mather J; Biohaven Pharmaceuticals, Inc., New Haven, CT, USA., Coric V; Biohaven Pharmaceuticals, Inc., New Haven, CT, USA., Numis AL; Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, USA., Sands TT; Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA., Millichap J; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Precision Epilepsy PLLC, Chicago, IL, USA., Berg AT; Decoding Developmental Epilepsies, Washington, DC, USA., L'Italien G; Biohaven Pharmaceuticals, Inc., New Haven, CT, USA. |
